title: Autoimmune hemolityc anemia after treatment of severe systemic lupus erythematosus with high-dose chemotherapy and autotransplantation of selected peripheral hematopoietic progenitors.
authors.affiliation: Servicio de Hematología, Hospital Son Dureta, Andrea Doria, 55, 07014 Palma de Mallorca, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Besalduch
authors.forename: Juan
authors.initials: J
authors.lastname: Bargay
authors.forename: Juan
authors.initials: J
authors.lastname: Buades
authors.forename: A
authors.initials: A
authors.lastname: Galmés
authors.forename: Miquel
authors.initials: M
authors.lastname: Morey
authors.forename: Antonia
authors.initials: A
authors.lastname: Sampol
mesh_terms: D000293:Adolescent; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D018952:Antigens, CD34; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D000069283:Rituximab; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018952:Antigens, CD34; D000970:Antineoplastic Agents; D000069283:Rituximab